UK FinTech Funding Fell Two-Thirds — And That May Be a Moat

UK FinTech investment fell to €2.1 billion (£1.8 billion) in the first half of 2026, down roughly two-thirds year-on-year and the lowest figure since KPMG's Pulse of FinTech report began in 2016. Deal count hit a ten-year low, according to KPMG. What capital remains is flowing to AI — and within AI, to products that show results fastest.

Running alongside the numbers is a story founders hear on every fundraising circuit: AI has collapsed the sales cycle, and products that once took a year to sell now close in a fraction of the time. The argument, as relayed by founders raising in the UK, is that anyone who cannot match that pace should question what they are building, or where.

A new opinion piece published on EU-Startups pushes back hard. For anyone selling into regulated financial services, the author argues, believing the fast-cycle story "is one of the fastest ways to put a good company out of business." The long sales cycle, the piece contends, is one of the few genuine strengths in this market — and it cannot be copied by other industries.

What does a regulated sale actually involve?

Selling AI to a mortgage network, a wealth manager or an advice firm means integrations into systems that were never built with an AI provider in mind. It means lengthy security reviews, multiple boards and committees each running on its own calendar, and several internal sponsors who must be won over separately and who do not all agree with each other. It also requires trust in the system and its output, backed by certifications from the usual ISO standards through to the new AI-specific ISO/IEC 42001.

In the UK, the procurement cycle has not sped up, the author writes. Regulated firms are accountable to the FCA for what their systems decide — a point the regulator's own Mills Review made plainly this summer. In compliance work, much of the output is binary: a file review or a financial promotions check is either right, or it is a regulatory problem. A heavily regulated product moving through several boards moves as slowly as it always has. The takeaway: the nine-month deal is normal, not broken.

Founders arriving with consumer expectations miss this. The companies telling the fast-cycle story are B2C, or B2B businesses that behave like B2C, according to the piece. The lesson travels; the conditions do not.

Is the cycle itself what kills startups?

No, the author argues — surprise is. A long cycle becomes dangerous only when a founder expects deals to close in weeks and sizes their funding round, hiring plan and investor conversations around that timeline. By month nine, the business can find itself with nothing closed and no fault in the product. Treated as a known quantity, the cycle is simply a parameter to design around.

Designing around it, the author writes, means unglamorous work:

• Size rounds so the money lasts through more than one full sales cycle.
• Hire people who have sold into regulated institutions before and know a fourth meeting with the risk committee is normal.
• Set investor expectations before the term sheet, not after the first missed quarter.
• Get certifications done early, because the security review will demand them regardless.

"Our investors describe the length of our sales cycle as a moat, and they are right," the author writes. The moat protects against naive entrants — usually industry insiders with strong product knowledge but no experience running a startup, who build something credible and run out of money before the first contract lands. The technology can be copied; the domain knowledge is widely held. Being set up to wait is the hardest thing to copy, because it must be built into funding, hiring and expectations from the start.

Should founders leave for the US?

The other conclusion founders are drawing from the funding numbers is that conditions will be better across the Atlantic. For some companies that holds, the author concedes; for others, the move deserves scrutiny. Europe, not America, holds the world's heaviest compliance burden: the most demanding regulators, the most complex rulebooks, and the customers with the strongest reason to buy. Leaving the market where the problem is most prominent because deals take longer is, in the author's words, a strange trade.

The slow lane, as the piece frames it, has three advantages. Fewer competitors, because most cannot afford to wait — and many who try, fail. Customers who stay, because a firm that spent a year taking a vendor through three committees has no appetite to repeat the exercise. And a market that rewards the one thing hard to fake: a company designed from its first round to survive the wait.

FinTech is not dying, the author concludes — parts of it are. Companies using AI to do work firms could not do before are growing quickly but selling slowly. The nine-month deal is not a flaw in regulated FinTech; it is the entry fee, and the founders still standing in two years will have paid it on purpose.